SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), an immuno-oncology
company developing cancer stem cell- related therapeutics, is pleased to
announce that it has raised gross proceeds of $33 million through a private
placement of units. The financing proceeds will be used to advance the Company's
CD47 cancer stem cell program through IND-enabling studies, manufacturing and
phase 1 clinical trials.


"The transformation of Stem Cell Therapeutics into a global competitor in the
immuno- oncology space requires a value-driving asset backed by world class
science, access to significant capital, experienced leadership, as well as a
strong and knowledgeable investor base. As of today we have all those
components," commented the company's CEO, Dr. Niclas Stiernholm.


The financing was led by a prominent U.S. healthcare fund, with participation
from several other premier U.S. healthcare institutional investors, including
Special Situations Funds, Ridgeback Capital, Merlin Nexus, Sabby Capital,
venBio, Opaleye Management and HSMR Advisors. Bloom Burton & Co. acted as lead
agent for the private placement. ROTH Capital Partners, LLC acted as placement
agent in the United States.


"The significant investment and validating sponsors hip from these reputable
life science- focused funds is the result of a concentrated effort to introduce
the U.S. investment community to our CD47 immune checkpoint program since the
acquisition of Trillium Therapeutics in April 2013," added Dr. Stiernholm.


In connection with the offering, the Company issued 157,142,858 units at a price
of $0.21 each. The units consisted of either one common share and three-quarters
of a common share purchase warrant ("Common Share Units") or one Series 1
Non-Voting First Preferred Share and three-quarters of a common share purchase
warrant ("Preferred Share Unit"). Of the total Units issued, 79,247,693 units
were Common Share Units and 77,895,165 units were Preferred Shares Units. Each
whole warrant entitles the holder to purchase one common share at a price of
$0.28 at any time prior to expiry on December 13, 2018. Following the offering,
the Company has 121,752,380 common shares issued and outstanding (144,031,618 on
a fully diluted basis).


The Company paid its agents a commission of 6% of the gross proceeds of the
offering (excluding subscription proceeds from certain President's list
subscribers), or $1,053,116, and issued a number of compensation warrants equal
to 6% of the units sold in the offering (except units sold to President's list
subscribers), or 5,014,839 compensation warrants. Each compensation warrant
entitles the holder to acquire one common share at an exercise price of $0.21
prior to expiry on December 13, 2015.


All securities issued under the offering (including the compensation warrants),
in Canada are subject to a four month hold and resale restrictions under
Canadian securities law, and in the United States are subject to statutory
resale restrictions under U.S. securities laws. All securities issued under the
offering are also subject to a four month hold imposed under the policies of the
TSX Venture Exchange.


Subscribers who purchased Preferred Share Units and certain subscribers who
purchased Common Share Units also agreed to be subject to restrictions on the
conversion and exercise of securities of the Company convertible in common
shares. Such subscribers cannot convert or exercise securities of the Company
convertible into common shares if, after giving effect to the exercise of
conversion, the subscriber and its joint actors would have beneficial ownership
or direction or control over common shares in excess of 4.99% of the then
outstanding common shares. This limit can be raised at the option of the
subscriber on 61 days prior written notice: (i) up to 9.99%, (ii) up to 19.99%,
subject to stock exchange clearance of a personal information form submitted by
the subscriber, and (iii) above 19.99%, subject to stock exchange approval and
shareholder approval.


Subject to receipt of any required regulatory approvals, subscribers who
purchased a minimum of 10% of the securities sold under the offering have been
given rights to purchase securities of the Company in future financings to
enable each such subscriber to maintain its percentage holding in the Company
for so long as the subscriber holds at least 10% of the outstanding common
shares on a fully-diluted basis.


About the CD47/SIRPa axis:

CD47 and SIRPa comprise an important immunoregulatory axis that controls
macrophage phagocytosis - the process by which target cells are engulfed and
destroyed. CD47 binds SIRPa on the surface of macrophages, and delivers a "do
not eat" signal that suppresses phagocytosis. There is strong evidence that many
blood-derived cancers and solid tumors exploit the CD47-SIRPa pathway to escape
macrophage-mediated destruction. This pathway is particularly relevant for
cancer stem cells, the rare populations of tumor cells with stem cell-like
properties that are often resistant to conventional therapies. SCT is developing
a soluble SIRPaFc fusion protein that binds to CD47 with high affinity and
blocks its interaction with cell surface SIRPa, enabling macrophages to kill
tumor cells in vitro (while sparing normal cells) and inducing potent anti-tumor
responses in vivo. It is being developed initially as a treatment for acute
myeloid leukemia, the most common acute leukemia in adults.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies.
Building on over half a century of leading and groundbreaking Canadian stem cell
research, the company is supported by established links to a group of prominent
Toronto academic research institutes and cancer treatment centers, representing
one of the world's most acclaimed cancer research hubs. The Company has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem cells in AML
and several other tumors. The CD200 mAb is a fully human monoclonal antibody
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-
cancer stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. An example of forward-looking
information in this news release includes the use of the proceeds of the
financing. These forward-looking statements involve risks and uncertainties that
may cause actual results, events or developments to be materially different from
any future results, events or developments expressed or implied by such
forward-looking statements. Such factors include changing market conditions; the
successful and timely completion of pre-clinical and clinical studies; the
establishment of corporate alliances; the impact of competitive products and
pricing; new product development risks; uncertainties related to the regulatory
approval process or the ability to obtain drug product in sufficient quantity or
at standards acceptable to health regulatory authorities to complete clinical
trials or to meet commercial demand; and other risks detailed from time to time
in SCT's ongoing quarterly and annual reporting. Except as required by
applicable securities laws, SCT undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.


The securities issued under the offering have not been, and will not be,
registered under the United States Securities Act of 1933, as amended (the "U.S.
Securities Act"), or any state securities laws, and accordingly, may not be
offered or sold within the United States except in compliance with the
registration requirements of the U.S. Securities Act and applicable state
securities requirements or pursuant to exemptions therefrom. This press release
does not constitute an offer to sell or a solicitation of an offer to buy any of
the Company's securities in the United States.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
ProActive Capital
Jeff Ramson
+1 646-863-6519
jramson@proactivecapital.com


ProActive Capital
Kirin Smith
+1 646-863-6519
ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From May 2024 to Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2023 to Jun 2024